NASDAQ:VCYT - Veracyte Stock Price, Forecast & News

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte Inc (NASDAQ:VCYT) released its earnings results on Tuesday, October, 22nd. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.05. The biotechnology company earned $30.97 million during the quarter, compared to analysts' expectations of $30.41 million. Veracyte had a negative return on equity of 5.33% and a negative net margin of 7.08%. View Veracyte's Earnings History.

Veracyte is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Veracyte.

2 brokerages have issued 1 year price targets for Veracyte's stock. Their forecasts range from $34.00 to $35.00. On average, they anticipate Veracyte's share price to reach $34.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price. View Analyst Price Targets for Veracyte.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

News coverage about VCYT stock has been trending very positive on Tuesday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a coverage optimism score of 3.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Veracyte.

Veracyte saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 2,610,000 shares, a decrease of 5.4% from the November 28th total of 2,760,000 shares. Based on an average daily trading volume, of 591,300 shares, the days-to-cover ratio is presently 4.4 days. Approximately 5.7% of the shares of the company are sold short. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), AbbVie (ABBV), InVitae (NVTA), Advanced Micro Devices (AMD), Exelixis (EXEL), NeoGenomics (NEO) and Netflix (NFLX).

Veracyte's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include KAMES CAPITAL plc (0.42%), California Public Employees Retirement System (0.32%), Falcon Point Capital LLC (0.10%), Assenagon Asset Management S.A. (0.07%), Strs Ohio (0.06%) and Calamos Advisors LLC (0.05%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Institutional Ownership Trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, California Public Employees Retirement System, Falcon Point Capital LLC, First Quadrant L P CA and Strs Ohio. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Insider Buying and Selling for Veracyte.

VCYT stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Assenagon Asset Management S.A., SG Americas Securities LLC, Exchange Traded Concepts LLC and FTB Advisors Inc.. View Insider Buying and Selling for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $27.44.

Veracyte has a market capitalization of $1.34 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

The official website for Veracyte is http://www.veracyte.com/.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]